

from UK public sources and encompassed annual drug costs (£268 FF/VI; £491 usual care), and COPD exacerbation management costs (moderate £114; severe £2,053).

Results Substituting usual care with FF/VI is likely to be associated with reduced COPD medication and exacerbation management costs. Total annual savings of £34,000 were obtained for a population of 1000 patients with COPD.


Conclusion In an everyday UK clinical setting, substituting usual care with FF/VI in patients with COPD can result in substantial annual cost savings. These results are relevant for clinicians and health care organisations.

P58 EFFICACY OF BUDESONIDE/FORMOTEROL IN COPD PATIENTS WITH A POST-BRONCHODILATOR FEV₁ 50 TO <70% OF PREDICTED NORMAL: POOLED ANALYSIS ACROSS FOUR PHASE III/IV STUDIES


¹C Jorup, ²GD James, ³K Pemberton, ¹G Eckerwall. ¹AstraZeneca RandD, Gothenburg, Sweden; ²PHASTAR Ltd, London, UK; ³AstraZeneca, Macclesfield, UK

10.1136/thoraxjnl-2016-209333.201

Background GOLD guidelines have changed from classifying COPD severity using pre-bronchodilator FEV₁ to classifying severity based on post-bronchodilator FEV₁. We therefore conducted a pooled *post-hoc* analysis of four budesonide/formoterol (Symbicort®) Turbuhaler® trials in COPD (which included patients based on pre-bronchodilator FEV₁), assessing efficacy and safety



†The LS mean is the difference between budesonide/formoterol and the comparison treatment in mean change from baseline FEV₁, determined by ANCOVA



‡The rate ratio is the exacerbation rate ratio between budesonide/formoterol and the comparison treatment, determined by a negative binomial model

ANCOVA, analysis of covariance; CI, confidence interval; FEV₁, forced expiratory volume in one second; LS, least squares; n, number of evaluable patients; PN, predicted normal

Abstract P58 Figure 1 Comparison of FEV₁ (A) and exacerbation rates (B) with budesonide/formoterol treatment vs placebo and vs formoterol for the FEV₁ 50-<70% PN subpopulation and the all-patient population. Pooled data across four phase III/IV studies

of budesonide/formoterol in the post-bronchodilator FEV₁50–<70% of predicted normal (PN) subpopulation versus the all-patient population. This analysis supported the EU label change for Symbicort[®] Turbuhaler[®] to: ‘symptomatic treatment of patients with COPD with FEV₁ < 70% PN (post-bronchodilator) and an exacerbation history despite regular bronchodilator therapy’.

Methods Four randomised, double-blind, active- and/or placebo-controlled, studies in patients with moderate to very severe COPD were analysed. Key study inclusion criteria were pre-bronchodilator FEV₁ ≤50% PN; use of short-acting bronchodilator; ≥1 exacerbation in the past 12 months. Primary endpoints for the analysis were 3-month pre- and 3- and 12-months post-bronchodilator FEV₁ and exacerbation rates at 3- and 12-months. Secondary endpoints included dyspnoea score, total symptom score, reliever medication use, night-time awakening and St George’s Respiratory Questionnaire. Results for the post-bronchodilator FEV₁50 – <70% PN subpopulation were compared with the all-patient population.

Results Of 3787 randomised patients, 832 (22.0%) had post-bronchodilator FEV₁50 – <70% PN. Baseline characteristics of the FEV₁50 – <70% subpopulation and the all-patient population were similar, except for baseline FEV₁ parameters. The benefit of budesonide/formoterol versus placebo and formoterol on the primary and secondary endpoints were generally consistent between the FEV₁50 – <70% subpopulation and the all-patient population across all four studies and in the pooled analysis (Figure 1). No new safety signals were identified.

Conclusions In patients with COPD, the clinical efficacy and safety of budesonide/formoterol compared with placebo and formoterol was consistent between the post-bronchodilator FEV₁50 – <70% PN subpopulation and the all-patient population, confirming the positive benefit/risk ratio in COPD patients with a post-bronchodilator FEV₁ <70% PN and a history of exacerbations.

P59 FACTORS INFLUENCING STEP-UP TO LAMA+LABA/ICS IN COPD PATIENTS INITIALLY ON LAMA MONOTHERAPY: A THIN DATABASE STUDY

¹JR Hurst, ²M Dilleen, ²K Morris, ²S Hills, ²B Emir, ³R Jones. ¹University College London, London, UK; ²Pfizer, New York, USA; ³Plymouth University Peninsula School of Medicine and Dentistry, Plymouth, UK

10.1136/thoraxjnl-2016-209333.202

The potentially inappropriate use of inhaled long-acting beta agonist/corticosteroid (LABA/ICS) combinations in COPD patients for whom this treatment is not recommended has clinical and economic implications.

This retrospective analysis of anonymized electronic medical records in the UK Health Improvement Network (THIN) database was conducted to identify factors associated with step-up from long-acting muscarinic antagonist (LAMA) to LAMA+LABA/ICS therapy. Secondary objectives included time to step-up, Global Initiative for Chronic Obstructive Lung Disease (GOLD) and Medical Research Council (MRC) classification. Data were included from COPD patients between 1 June 2010 and 4 September 2014, aged ≥35 years at first LAMA treatment, with continuous enrolment >360 days before the index event (date of first LAMA prescription) who received LAMA monotherapy only prior to step-up. Time to step-up was analysed using

a Cox regression model with time-varying covariates using a step-wise model selection procedure.

Data from 8773 patients (6199 LAMA [136 deaths]; 2438 LAMA+LABA/ICS) were included. Multivariable analysis revealed that exacerbations (composite), elective secondary care contact, markers of COPD proactive planned care, and reactive COPD care within the primary care setting were clinically and statistically significantly associated with step-up. Statistically significant factors negatively associated with step-up were being female and having diabetes (Table). Univariate analysis revealed FEV₁, COPD severity and MRC classification to be significant predictors of step-up. These were not included in the multivariable model due to reduced observations, but sensitivity analyses including each in turn confirmed the above predictors. 28% of the cohort received step-up therapy, the majority (23%) within 2 years of LAMA monotherapy initiation. Assessment per GOLD classification suggests that step-up was appropriate in most patients (group A, 18%; B, 21%; C, 26%; D, 35%). Assessment of MRC score (mean, median) in the step-up group (baseline: 2.45, 2.00; follow-up: 2.74, 3.00) suggests that patients who were stepped-up became more symptomatic prior to step-up.

These results show that COPD exacerbations were the most significant predictor of therapy step-up and that patients with initially stable disease are unlikely to require step-up. Therapy step-up appears to be appropriate in the majority of, but not all patients, and may reflect adherence to national guidelines.

Abstract P59 Table 1

Variable	Multivariate Cox Regression Analysis		
	HR	95% CI	P-value
Composite: exacerbations ^a	2.380	2.170, 2.611	<0.0001
Elective secondary care contact	1.445	1.305, 1.601	<0.0001
Markers of COPD proactive planned care within primary care setting	1.268	1.231, 1.305	<0.0001
Reactive COPD care within primary care setting	1.155	1.115, 1.198	<0.0001
Composite: cardiovascular ^b	1.150	1.025, 1.291	0.0175
Number of cough symptoms	1.086	1.046, 1.128	<0.0001
Number of short-acting bronchodilator prescriptions	1.033	1.027, 1.038	<0.0001
Age at index date ^c	0.992	0.988, 0.995	<0.0001
Sex (female)	0.798	0.735, 0.867	<0.0001
Diabetes	0.685	0.530, 0.886	0.0039

AECOPD, acute exacerbation of COPD; CI, confidence interval; HR, hazard ratio.

^aExacerbations (COPD emergency admission or AECOPD or lower respiratory tract infection or oral corticosteroid + antibiotic)

^bCombined comorbidity for cardiovascular risk (heart failure, congestive heart disease, hypertensive disease, cerebrovascular disease, atrial fibrillation)

^cHR relative to change to every 1 year difference in age.

P60 EFFECT OF INDACATEROL/GLYCOPYRRONIUM (IND/GLY) ON PATIENT-REPORTED OUTCOMES IN MEN AND WOMEN WITH COPD: A POOLED ANALYSIS FROM THE IGNITE PROGRAMME

¹K Kostikas, ²I Tsiligianni, ³S Fucile, ¹K Mezzi, ³S Shen, ³D Banerji, ³R Fogel. ¹Novartis Pharma AG, Basel, Switzerland; ²Clinic of Social and Family Medicine, University of Crete, Heraklion, Crete, Greece; ³Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA

10.1136/thoraxjnl-2016-209333.203

Introduction Literatures, although limited, suggest differences in the manifestations of COPD in terms of symptoms and health-related quality of life between men and women. Moreover, a